Health · NYSE ARCA · USD · Data as of 2026-07-30
AUM
$52.68M
Expense ratio
0.65%
Yield
1.24%
YTD return
+36.19%
Last price
$48.47
Thematic Sector · Coverage 100% · medium
Today
38.4
Outlook
45.7
Block A (composite-derived)
46.6
Block C (market behavior)
31.5
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
46.6
Coverage 100% · high
Liquidity
25.0
Expenses
45.0
Performance
63.6
Volatility
3.9
Dividend
19.0
Concentration
85.0
Smart Money
56.8
Activist
98.5
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund from Virtus in the Mixed asset class. Launched in 2014. Assets under management: 37,332,492.
The fund tracks the LifeSci Biotech Clinical Trials Index.
Bullish Whales composite rating: 47 out of 100. Evidence coverage 100% across 8 of 8 axes. Strongest axes: activist exposure, concentration, performance.
Annualized one-year realized volatility 36%, classified high. Weakest axes: volatility, dividend.
Top-10 weight 0%, diversified, led by ERAS. Trailing yield 0%.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, dividend_score, performance_score, volatility_scoreetf_fundamentals_td · dividend_frequency, yieldetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, benchmark, benchmark_provider, fund_type, inception_date, issuer, name, replication_method, ticker, volatility_1yVirtus LifeSci Biotech Clinical Trials ETF is an exchange-traded fund that focuses on providing investors exposure to the biotechnology sector, specifically targeting companies engaged in the clinical trials phase of drug development. The primary function of this ETF is to track the performance of the LifeSci Biotech Clinical Trials Index, which includes firms that are in the critical stages of clinical development for new therapeutic treatments. This ETF invests in businesses that are small to mid-cap biotech companies, which are pivotal in the innovation and advancement of medical and pharmaceutical solutions. By concentrating on companies involved in clinical trials, the fund offers unique access to an essential segment of the biotech industry that is directly involved in bringing potentially groundbreaking treatments from concept to market. As these companies operate in a high-risk, high-reward phase of the drug approval process, the ETF plays a significant role for investors looking to gain diversified exposure to emerging biotechnologies with the potential for significant impacts on health care and medicine. The Virtus LifeSci Biotech Clinical Trials ETF is a strategic instrument for those monitoring technological advancements and therapeutic innovations within the life sciences sector.
30-day change
$8.05M
90-day change
—
Current AUM: $52,678,624. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BBC are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.